Cidara Therapeutics, Inc.

Merck Sharp + Dohme Corp.

Lawrence Livermore National Security, LLC

Voon Ong

Min Teng

John F Finn

Kenneth Bartizal

Paul Daruwala

Taylor Sandison

Dirk Thye

Maureen Roden

John M Finn

Xiaoming Li

Junhu Zhang

Allen Borchardt

Zhiyong Chen

Leslie William Tari

Thanh To Lam

Michael Trzoss

Douglas W Phillipson

Sergio E Wong

Felice C Lightstone

Suk Joong Lee

Daniel Bensen

Toan B Nguyen

Jeffrey Brian Locke

Allen John Borchardt

The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).

Dosing regimens for treatment of fungal infections

The disclosure relates to methods of prophylactic and therapeutic treatments of ainfection (i.e., an infection caused by) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of aspp. The methods of the disclosure can be useful in immunocompromised subjects.

Methods for preventing and treating pneumocystis infections

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

Tricyclic gyrase inhibitors

The disclosure relates to methods of prophylactic and therapeutic treatments of ainfection (i.e., an infection caused by) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of aspp. The methods of the disclosure can be useful in immunocompromized subjects.

Growing community of inventors

San Diego, CA, United States of America

Voon Ong